AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05129176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole-tetracycline-containing quadruple regimens
Study NCT06422520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-C354
Description: Administered by intravenous infusion
Study NCT06422520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered by intravenous infusion
Study NCT06740149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (high dose)
Description: Administered intravenously. For phase I: single infusion, 4×10\^6 cells /kg.
Study NCT05014542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture treatment includes pricking the skin with acupuncture needles 0.3 x 40 millimetres in size, in the places of prescribed acupuncture points. Placed needles should be manipulated three times, every ten minutes, three times in total. The complete time of treatment is 30 minutes. All treatments will be equal.
Study NCT05014542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Medical Treatment
Description: Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
Study NCT05014542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Treatment
Description: Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: A. afra infusions of 5g/500ml of water, 2drinks a day, daily for 1week (7 days) (increase concentration and decrease dose frequency).
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: A. afra infusions,5g/1liter of water, 3drinkss a day, weekly for 4weeks (decrease dose frequency and increase length of treatment).
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: A. afra infusions, 5g/1liter of water, 3drinks a day, daily for1week (7 days) (current treatment with improved taste).
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: A. afra infusions, 5g/500ml of water, 2drinks a day, daily for 1 week (7 days) (improved taste, increase concentration and decrease dose frequency).
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artemisia afra tea infusions
Description: Group of 8 persons receiving flavored A. afra infusions, 5g/1liter of water, 3drinks a day, weekly for 4weeks (improved taste, decrease dose frequency and increase length of treatment).
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored placebo infusions
Description: Flavored placebo infusions, 5g/liter of water, 3drinks a day, daily for 1week (7 days) (improved taste with no active molecule)
Study NCT05440773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular tea placebo
Description: Regular tea placebo taken as desired, daily for 1 week (7 days) (Regular tea with no active molecule).
Study NCT06023576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antihypertensive medications
Description: One or more of the following medications may be used in both randomization groups to achieve SBP goals:~* Angiotensin converting enzyme inhibitors (ACEI)~* Angiotensin receptor blockers (ARBs)~* Beta-blockers (BB)~* Thiazide-type diuretics~* Calcium channel blockers~* Aldosterone antagonists~* Alpha1-receptor blockers.~* Direct vasodilators~* Loop diuretics
Study NCT06023576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Description: Home BP Monitoring (HBPM)-Throughout the study period, patients will perform HBPM at baseline, month 6, and month 12 (end of treatment). At each of these timepoints, HBPM will be performed for 7 days with 2 morning and 2 evening readings for each day (measured 1-min part).
Study NCT06739837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: Participants in this arm will undergo traditional physiotherapy exercises for managing tennis elbow.
Study NCT06739837 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Non-immersive VR therapy
Description: Participants undergo a VR-based rehabilitation program targeting tennis elbow symptoms. Sessions last 30 minutes, conducted 3 times per week for 6 weeks. Exercises focus on improving grip strength, wrist flexibility, and functional movement through interactive VR environments that visually engage the affected arm, promoting adherence and motivation without full immersion. The VR setup includes headsets or screens that enable visual interaction, enhancing the rehabilitation experience. The goal is to alleviate pain, increase range of motion, and restore muscle strength.
Study NCT06741007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroperitoneal pelvic lymphatic and uterine vessel dissection
Description: ICG injection to cervix uteri at 3 and 9 o'clock followed by laparoscopic dissection of retroperitoneal space to detect uterine vessels (uterine arteries, SUVs and DUVs) bilaterally in addition to detect the location and biopsy of SLN stained by ICG.
Study NCT06739746 — intervention group
Intervention type: OTHER
Intervention: No intervention measures
Description: No intervention measures
Study NCT06740123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment and application of H42® hydrogel to the peri-implant pocket
Description: Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
Study NCT06740123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment of periodontal pocket
Description: Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant.
Study NCT06023576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiogram
Description: At baseline, month 6, and month 12
Study NCT06023576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom-limited cardiopulmonary exercise test
Description: Consecutive patients in each treatment group who meet the eligibility criteria for exercise testing will be offered to participate in CPET at the time of consent. Patients who agree will undergo CPET (baseline, 6 months, and 12 months) until the target accrual of 33 patients per group is met.
Study NCT06740123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment and application of H42® hydrogel to the periodontal pocket
Description: Firstly, after appropriate oral hygiene training, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of periodontal pocket areas between 5-8 mm in the contralateral quadrant. The tested site will be partially isolated and then air-dried. A bent, blunt-tipped needle syringe will be used to inject the H42® hydrogel into the pocket, ensuring that the tip reaches the deepest point of the pocket. Once the gel is visible at the gingival margin, the needle will be gently removed from the pocket. After approximately 0.1 mL of gel has been applied, excess gel will be removed with a sterile gauze swab to prevent any spreading effect or possible systemic effect. After application of the H42 hydrogel, the area will be kept dry for 5 minutes to ensure optimum adhesion of H42 to the pocket tissue.
Study NCT06740123 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment of peri-implant pocket
Description: Systemic and dental anamnesis will be taken from all patients. Firstly, after appropriate oral hygiene education, full mouth supragingival scaling will be performed using an ultrasonic device (EMS Piezon ultrasonic system, EMS Electro Medical Systems, Switzerland). Non-surgical periodontal treatment will be completed after subgingival curettage of peri-implant pocket areas between 5-8 mm in the contralateral quadrant.
Study NCT06736782 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Empowerment Care Intervention Group
Description: The intervention emphasizes four key principles: hydration, exercise, dietary support, and defecation care. Each component is designed to address fundamental needs and promote independence in activities of daily living (ADLs).~Individualized care plans will be developed in collaboration with healthcare professionals and caregivers to ensure alignment with participants' functional capabilities and personal goals.
Study NCT06736782 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Standard caregiving practices without emphasis on structured hydration, exercise, or dietary programs.~General assistance with ADLs as per existing care routines in the respective facilities.
Study NCT06736951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MMSH (Multi-Modal Sleep Hygiene) Bundle
Description: Focus on Noise Reduce Noise Perception, Reduce Hallway Noise, Reduce Noise in Rooms Focus on Light Reduce Lights at Night, Increase Light in Day, Reduce Light Perception Focus on Staff-Patient Interactions Delirium Screening, Avoid Care Procedures at Night, Z-time Plan \&amp; Prep Focus on Daytime Activity Increased Mobility, Increase Patient Engagement Focus on Medications Pain Management, Medication Monitoring, Continue pharmacy protocols, Timing of Medications/Monitoring Labs
Study NCT06739733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SRG
Description: Soft robotic gloves stimulation 30-minute sessions, 5 times per week upto 8 week Soft robotic gloves are assistive devices designed to enhance hand function for individuals with disabilities or injuries. These gloves use flexible materials, such as silicone or fabric, combined with pneumatic or cable-driven mechanisms to mimic natural hand movements. They provide assistance for gripping, holding, or manipulating objects, often controlled by sensors or user inputs. Soft robotic gloves are lightweight, adaptable, and offer rehabilitation potential, helping restore motor function in conditions like stroke or spinal cord injury. They are increasingly used in clinical and home-based therapy settings.
Study NCT06739733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Electrical muscle stimulation 30-minute sessions, 5 times per week upto 8 weeks.~Electrical Muscle Stimulation (EMS) is a technique that uses electrical impulses to contract muscles, often used for rehabilitation, strength training, or pain management. Electrodes placed on the skin deliver controlled currents to target specific muscle groups, mimicking natural nerve signals. EMS is commonly used in physiotherapy to prevent muscle atrophy, improve circulation, and enhance recovery after injury. It is also utilized in fitness and sports for performance enhancement. Safe and non-invasive, EMS can be adjusted for therapeutic or functional goals.
Study NCT06609889 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ION283
Description: Anti-sense Oligonucleotide therapy that includes intrathecal (IT) injections by lumbar puncture (LP) with dose level of 15 mg.
Study NCT04992390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief digital imagery-competing task intervention
Description: First session guided by a researcher: A memory cue followed by playing the brief digital imagery-competing task with mental rotation instructions.~Option to engage in self-administered/guided sessions after the first session and record their intrusive memories (symptom monitoring).
Study NCT06023576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Measures
Description: FACT-B, Fatigue Symptom Inventory (FSI), Patient Reported Outcomes Measurement Information System (PROMIS) Global Health Scale, Godin Leisure Time Exercise Questionnaire (GLTEQ),PROMIS Medication Adherence Scale. Given baseline, 3 months and 12 months.
Study NCT06023576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Research blood samples will be collected at baseline, 3 months, and 6 months
Study NCT06329843 — intervention group
Intervention type: DEVICE
Intervention: Picterus Jaundice Pro (JP)
Description: Picterus Jaundice Pro photos will be obtained of enrolled subjects each time the patient has a serum bilirubin level obtained. Up to five paired measurements will be obtained per enrolled subject. The study nurse will place the proprietary calibration card over the subject's sternum and take six Picterus Jaundice Pro photos using a study iPhone within one hour of the serum bilirubin draw. This process takes less than one minute. After the study photos are obtained, the study nurse will record the serum and Picterus Jaundice Pro values in the data-recording log.~In the event an enrolled infant requires phototherapy, a light occlusive adhesive patch will be placed over the center of the chest before phototherapy initiation. When a serum bilirubin level is obtained, the research nurse will remove the patch for a brief moment to take Picterus Jaundice Pro pictures (within one hour of the serum value draw).
Study NCT04511039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study NCT04511039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Tosylate
Description: Given PO
Study NCT05194917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Older Smoker Motivational Intervention
Description: OSMI identified in Aim 2 of the study, motivational interventions will be delivered via mailer with QR video code.
Study NCT05194917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Motivational Message
Description: One control motivational message with a standard health- and EBST access-related content (i.e., Quitting smoking is the best thing you can do for your health. Call 1-800-QUIT-NOW for help.), motivational interventions will be delivered via mailer with QR video code.
Study NCT06207344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine and propofol
Description: Group 1: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. Meantime, propofol was infused at 4-12mg/kg/h intravenously to maintain the depth of anesthesia.
Study NCT06207344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and desflurane
Description: Group 2: After anesthesia induction, dexmedetomidine was infused at 1 μg/kg intravenously within 15 min, then infused at 0.3 μg/kg/h until 30 min before the end of the operation. At the same time, 2.5%-8.5% desflurane was inhaled to maintain the depth of anesthesia.
Study NCT04310137 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Directed Re-loading
Description: Therapist will specifically direct participant to increase walking by 10% as measured at each of the activity monitoring assessments. In addition, the participant will be asked to monitor foot temperature to mitigate risk for breakdown.
Study NCT05324033 — intervention group
Intervention type: RADIATION
Intervention: multiparametric MRI on the bladder
Description: comparison between mpMRI and histopathology
Study NCT05324033 — intervention group
Intervention type: PROCEDURE
Intervention: diagnostic cystoscopy +/- TURBT
Description: conventional way of diagnosis
Study NCT06316323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: 38% Silver Diamine Fluoride (SDF) is a topical antimicrobial and remineralizing agent which was cleared by the FDA as a Class II medical device to treat tooth sensitivity. In certain circumstances, SDF may be used as a non-restorative treatment to arrest carious lesions on primary and permanent teeth
Study NCT06316323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride
Description: Fluoride varnish to apply on tooth surface, so that the tooth becomes more resistant to caries attack. The active ingredient of fluoride varnish is 5% sodium fluoride, (22,600 ppm fluoride)
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 6 mg/m2 daily subcutaneously for consecutive 3 days (day 1 to day 3)
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony-Stimulating Factor
Description: 5ug/kg/d when absolute neutrophil count ≤ 1.5 × 109/L
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombopoietin Receptor Agonist
Description: Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thrombopoietin Receptor Agonist
Description: Eltrombopag initial dose: 25 mg orally once a day, may increase to up to 75 mg/day, when platelet count ≤ 30 × 109/L; Avatrombopag initial dose: 20 mg orally once a day, may increase to up to 60 mg/day, when platelet count ≤ 30 × 109/L.
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Description: 10000 U/day when hemoglobin ≤ 85 g/L
Study NCT05907499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: 10000 U/day when hemoglobin ≤ 85 g/L
Study NCT04792970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talc
Description: All patients randomized to the Talc arm will receive Talc therapy through the pleural catheter.
Study NCT04880590 — intervention group
Intervention type: OTHER
Intervention: Sex intercourse
Description: A heterosexual sexual relationship
Study NCT05821647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPI guided treatment advice
Description: Administer hemodynamic altering intervention aimed at either a preload, contractility, or afterload problem to prevent impending hypotension. Treatment options include: administering either fluids, inotropes, vasopressors, positional changes, or a combination.
Study NCT05713955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Obsidian
Description: To create OBSiDiAN BioMatrix, 120 ml of the the patient's blood is added to the processing unit. The Vivostat® processor unit heats, separates, centrifugates to get the plasma. Batroxobin is added. After again processing, the result is an OBSiDian syringe filled with BioMatrix Obsidian®ASG. This will be applied on the anastomosis
Study NCT06081465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG290131
Description: The study drug and matching placebo will be administered orally.
Study NCT06512090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LGI steam bread
Description: LGI Steam bread called Mangusteam bread
Study NCT06512090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diabetic diet
Description: the calorie intake of Diabetic diet will by recommended by nutritionist
Study NCT05610150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myobrace Functional Appliance
Description: An Appliance for treating growing Class II patients with mandibular deficiency
Study NCT05610150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block
Description: An Appliance for treating growing Class II patients with mandibular deficiency
Study NCT06511427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: upper airway sonography
Description: clinical evaluation of upper airway, ultrasonographic assessement